Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway-Reference-Cited by-同舟云学术

Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway

Published:2023-01 Issue: Volume:168 Page:83-91
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Yanaihara Nozomu,Yoshino Yuki,Noguchi Daito,Tabata Junya,Takenaka Masataka,Iida Yasushi,Saito Misato,Yanagida Satoshi,Iwamoto Masami,Kiyokawa Takako,Chiba Natsuko,Okamoto Aikou

Funder

Japan Society for the Promotion of Science

Terumo Foundation for Life Sciences and Arts

Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference23 articles.

1. PARP inhibitors for ovarian cancer: current indications, future combinations, and novel assets in development to target DNA damage repair;Konstantinopoulos;Am. Soc. Clin. Oncol. Educ. Book.,2020

2. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer;Coleman;N. Engl. J. Med.,2019

3. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial;Aghajanian;Gynecol. Oncol.,2022

4. BRCA1/ATF1-mediated transactivation is involved in resistance to PARP inhibitors and cisplatin;Endo;Cancer Res. Commun.,2021

5. Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency;Yoshino;Sci. Rep.,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition;Acta Biochimica et Biophysica Sinica;2023-12-01

2. DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review;Pharmacological Research;2023-10

3. Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway;2023-08-10

4. Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity;iScience;2023-07